Skip to main content

Advertisement

Table 1 Clinical information of serum of normal control and patients with various cancers

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

Breast carcinoma Non-small Cell Lung Cancer (NSCLC) Colorectal carcinoma Kidney carcinoma Normal control
Characteristics Characteristics Characteristics Characteristics Characteristics
No. of samples 197 No. of samples 111 No. of samples 64 (Rectal 14) No. of samples 30 No. of samples 100
Female 197 Male 50 Male 33 (Rectal 7) Male 17 Male 50
Mean age (years) 48.54 ± 18.43 (20–91) Female 61 Female 31 (Rectal 7) Female 13 Female 50
Stage I 66 (35:31)* Mean age (years) 41 ± 10.39 (41–85) Mean age (years) 63.84 ± 12.20 (39–78) Mean age (years) 55.07 ± 11.22 (34–76) Male mean age (years) 44.54 ± 14.85 (20–76)
Stage II 70 (37:33) Stage I 39 (IA 19, IB 20) Stage I 6 Stage I 26 Female mean age (years) 43.70 ± 14.95 (18–71)
Stage III 61 (34–27) Stage II 32 (IIA 16, IIB 16) Stage II 36 (Rectal 7) Stage II 4 Female/Male 44.12 ± 14.83
Lobular type 106 Stage III 30 (IIIA 21, IIIB 90) Stage III 22 (Rectal 7) Mean age (years) (18–76)
Ductal type 91 Stage IV 10       
  1. All sera obtained from Caucasian White.
  2. *First and second values are # of lobular and ductal carcinoma breast cancer.